EP3463206A1 - Vasospasmusbehandlung - Google Patents
VasospasmusbehandlungInfo
- Publication number
- EP3463206A1 EP3463206A1 EP17733977.7A EP17733977A EP3463206A1 EP 3463206 A1 EP3463206 A1 EP 3463206A1 EP 17733977 A EP17733977 A EP 17733977A EP 3463206 A1 EP3463206 A1 EP 3463206A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- stent structure
- wires
- struts
- proximal
- vasospasm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010047163 Vasospasm Diseases 0.000 title claims abstract description 27
- 238000003780 insertion Methods 0.000 claims abstract description 26
- 230000037431 insertion Effects 0.000 claims abstract description 26
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 238000000576 coating method Methods 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 16
- 230000002965 anti-thrombogenic effect Effects 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 206010002329 Aneurysm Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- 229960000715 nimodipine Drugs 0.000 description 3
- 230000002883 vasorelaxation effect Effects 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 238000000418 atomic force spectrum Methods 0.000 description 2
- 238000003698 laser cutting Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- JTUQXGZRVLWBCR-UHFFFAOYSA-N 1-[1-[2-(phenylmethyl)phenoxy]propan-2-yl]piperidine Chemical compound C1CCCCN1C(C)COC1=CC=CC=C1CC1=CC=CC=C1 JTUQXGZRVLWBCR-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/844—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents folded prior to deployment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/9522—Means for mounting a stent or stent-graft onto or into a placement instrument
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0006—Rounded shapes, e.g. with rounded corners circular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0017—Angular shapes
- A61F2230/0019—Angular shapes rectangular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0091—Three-dimensional shapes helically-coiled or spirally-coiled, i.e. having a 2-D spiral cross-section
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0015—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in density or specific weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0036—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in thickness
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0039—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
Definitions
- the invention relates to a device with a stent structure intended to be introduced into blood vessels of the human or animal body, wherein the stent structure has an expanded state in which it bears against the inner wall of the blood vessel and a contracted state in which it is inside a microcatheter is movable through the blood vessel, wherein the stent structure, preferably at its proximal end, is connected to an insertion aid.
- stents are often used to treat vasoconstriction and permanently implanted at the site of vasoconstriction to keep the vessel open.
- stents have a tubular structure and are either laser-cut so as to provide a surface of struts between which there are openings, or consist of a wire mesh.
- Stents can be brought to the target site through a catheter and expanded there; in the case of self-expanding stents made of shape memory materials, this expansion and the application to the vessel inner wall is carried out independently.
- stents may also be expanded by means of balloons crimped on the stent or other mechanical procedures.
- vasospasm is a spasmodic constriction of a blood vessel. This is associated with the risk that subsequent vessels will no longer be adequately supplied with blood (ischemia), which may lead to necrosis of the tissue supplied with blood by the blood vessels. Especially in the cerebral area, a vasospasm may occur some days after a subarachnoid hemorrhage. As such, vasospasm is one of the major causes of strokes, including deaths, following a rupture of an aneurysm and / or bleeding from the same or an operation in this area.
- a vasospasm is treated by medication, in particular Caiciumkanalblocker or drugs are used, which increase the NO level in the blood.
- medication in particular Caiciumkanalblocker or drugs are used, which increase the NO level in the blood.
- An example of a Caiciumkanalblocker is nimodipine, which is often used after subarachnoid hemorrhage to prevent vasospasm.
- nimodipine which is often used after subarachnoid hemorrhage to prevent vasospasm.
- the drug treatment is associated with not insignificant side effects and also costly and time-consuming. It was therefore the task of providing means that allow the treatment of vasospasm in other ways.
- a device having a stent structure, which is intended to be introduced into blood vessels of the human or animal body, wherein the stent structure has an expanded state in which it bears against the inner wall of the blood vessel and has a contracted state, in which it is movable within a microcatheter through the blood vessel, wherein the stent structure, preferably at its proximal end, connected to an insertion aid and the device for the treatment of vasospasm is used.
- the stent structure preferably at its proximal end, connected to an insertion aid and the device for the treatment of vasospasm is used.
- the stent structure does not remain permanently in the blood vessel, so it is not implanted, but used only temporarily and removed after a few minutes. A detachment point between stent structure and insertion aid is therefore not required.
- a stent structure which is self-expanding and, after release from the microcatheter, automatically transitions to the expanded state.
- a stent structure made of a material with shape memory properties is advantageous, in particular, the use of nickel-titanium alloys has proven to be known under the name Nitinol.
- polymers with shape memory properties or other alloys are also conceivable.
- the device according to the invention can be used in particular in the neurovascular area, but it is also possible to use it in the cardiovascular or peripheral area.
- the insertion aid is typically an insertion wire, also called a guide wire.
- insertion wires are also used for implants; however, for implants intended to remain permanently in the vascular system, the introducer wire is connected to the implant via a detachment point, the detachment point being able to be provided for mechanical, thermal or electrolytic detachment.
- the device according to the invention is only temporarily brought to the site of vasospasm, where an expansion of the stent structure takes place.
- the insertion aid is preferably made of stainless steel, nitinol or a cobalt-chromium alloy.
- the insertion aid or the insertion wire is preferably attached to the proximal end of the stent structure radially outside.
- the connection of introducer and stent structure is not in the center of the stent structure, but eccentrically at or near the vessel inner wall. This way will the blood flow impeded as little as possible.
- the eccentric placement of the introducer also facilitates retraction of the device into the microcatheter.
- the insertion aid it is also possible to connect the insertion aid at several points with the stent structure, preferably with the proximal end of the stent structure.
- Multiple connection points with the stent structure on the one hand cause a slightly greater obstruction of blood flow due to the additional struts or wires extending in the center of the blood vessel.
- the proximal end of the stent structure which runs out towards the insertion aid and therefore no longer bears completely against the vessel inner wall and can exert essentially no radial forces on it, can be kept shorter.
- the insertion aid is usually more central.
- the treatment is carried out in such a way that the device according to the invention within a microcatheter to the destination, d. H. the place of vasospasm is advanced.
- the stent structure is subsequently released, which then expands and abuts the inner wall of the vessel and treats the vasospasm.
- the stent structure is left for a short time, typically 1 to 10 minutes.
- the microcatheter is again moved distally to fold in the stent structure and the microcatheter, together with the device, is withdrawn.
- the treatment may be repeated on several consecutive days.
- proximal and distal are to be understood as meaning that, when the device is introduced to the attending physician, parts are referred to as proximal, parts facing away from the attending physician are referred to as distal.
- the device is thus typically advanced distally through a microcatheter.
- axial refers to the proximal to distal longitudinal axis of the device, the term “radial” to perpendicular thereto planes.
- a medicamentous treatment can also be carried out, for example with nimodipine. This can in particular be applied intra-arterially at the site of the vasospasm.
- the stent structure can be composed of individual, interconnected webs or struts.
- Such a stent structure can be produced by laser cutting in a basically known manner.
- it makes sense to subject the stent structure to electropolishing to make it smoother and more rounded and less traumatic.
- the danger of attachment of germs or other impurities decreases.
- the stent structure may also be a mesh structure of individual wires forming a mesh.
- the wires typically run helically along the longitudinal axis, with counter-running wires running over and under one another at the points of intersection, so that honeycomb-shaped openings are formed between the wires.
- the total number of wires is preferably 8 to 64.
- the wires forming the mesh structure may be single metal wires, but it is also possible to provide strands, i.e., wires. H. multiple wires of small diameter, which together form a filament and are preferably twisted together.
- An advantage of a stent structure of interconnected webs or struts, which is generated in particular by laser cutting, compared to a mesh structure of wires is the fact that a stent structure of struts on expansion is less prone to length contraction than a mesh structure.
- the length contraction should be kept as small as possible, since the stent structure exposes the surrounding vessel wall to additional stress during a length contraction. Since a vasospasm is ultimately due to stimuli that are exerted on the vessel, an additional burden in vasospasm treatment is to be avoided.
- a stent structure of interconnected struts is also advantageous in that the radial force exerted by such a stent structure with otherwise comparable structure, strut / wire density and strut / wire thickness is higher than that of a mesh structure made up of wires.
- the reason is that the struts have a fixed connection at the points of intersection, while the wires of a mesh structure generally run only above and below each other.
- the struts or wires may have a round, oval, square or rectangular cross-section, wherein in the case of a square or rectangular cross section, a rounding of the edges is advantageous.
- the apertures formed in the stent structure between the individual struts or wires should have a inscribed diameter of 0.1 to 6 mm, the inscribed diameter being understood to mean the diameter of the largest circle that can be placed in the aperture.
- the data relate to the stent structure in the expanded state, d. H. the state that the stent structure assumes when it is not exposed to external constraints.
- a stent structure having a diameter in the expanded state of 3 to 5 mm may have an inscribed diameter of the openings of 2 to 4.5 mm.
- the resulting in the stent structure openings should be closed all around, d. H. without interruptions of struts or wires (so-called "closed-cell design"), since this facilitates the conveyance of the stent structure after the treatment in the microcatheter by postponing it.
- struts or wires with a relatively large cross section or diameter ie the use of relatively massive struts / wires.
- a height and a width of the struts / wires of 30 to 300 ⁇ have been found to be advantageous, with a rectangular cross-section with rounded edges is considered to be substantially rectangular.
- the diameter should be between 30 and 300 ⁇ .
- the stent structure is open at the proximal end. At the distal end, the stent structure can also be open, but also closed.
- a bilateral open stent structure has the advantage that the blood flow is disturbed as little as possible and a shortage of subsequent blood vessels and the tissue supplied by this prevented.
- a closed structure at the distal end is atraumatic. Under open is understood here that at the respective end of the stent structure no struts or wires are present and struts / wires are limited to the outer circumference of the stent structure. By contrast, with a closed end, struts or wires are also present in the center of the stent structure.
- a vasorelaxant coating is advantageous, for example with a calcium channel blocker such as nimodipine.
- the antithrombogenic or vasorelaxant coating can also be applied overall to the stent structure or the struts / wires can have a corresponding one on all sides Have coating.
- the coating is not limited to the inside or outside of the stent structure. In general, it has to be said with regard to all coatings that they can also relate only to a part or a partial length of the stent structure in each case. Of importance is a coating, in particular in the areas of the stent structure, which touch the vessel inner wall, ie substantially the cylindrical part of the stent structure.
- the force acting radially outward on the vessel inner wall through the expanded stent structure should be between 2 and 16 N / m, preferably between 5 and 8 N / m.
- the indication of the radial force refers to the force per unit length of radial force, d. H. it is the relative radial force. Only the part of the stent structure is taken into account, which bears against the vessel inner wall and is therefore able to exert forces on it (effective length). Along the effective length, the stent structure must cover at least 50% of a sheath drawn around the stent structure.
- the absolute radial force refers to the total value of the stent structure.
- the determination of the radial force applied by the stent structure (Chronic Outward Force, COF) is carried out in the following way by means of a V-block test:
- the test setup of the V-Block test consists of two polymethylmethacrylate (PMMA) blocks, each with a milled and smooth polished 90 ° V groove. These V-blocks are placed one above the other in such a way that, when the blocks come into contact, a cavity with a square cross-section is created. While one of the V-blocks is fixed, the other is provided with a force sensor.
- PMMA polymethylmethacrylate
- the COF describes the force exerted by the stent structure on its self-expansion on the blood vessel or in the test the V-blocks.
- the stent structure is positioned midway between the V-blocks within a transport tube or microcatheter. Subsequently, the transport tube / microcatheter is withdrawn and the stent structure is released. Because of its self-expanding properties, it expands and the radial force emanating from the stent structure can be measured and evaluated via the force sensor connected to one of the V blocks.
- the relative radial force is calculated:
- the radial force exerted by the stent structure in the expanded state over the length is substantially constant, d. H. in the proximal portion and the distal portion, the radial force corresponds to that of the middle portion.
- the actually acting radial force in the proximal and distal sections is generally weaker than in the middle section.
- proximal end of the stent structure on which the struts or wires typically no longer completely rest against the vessel inner wall, for which radial force is disregarded.
- the proximal end thus designates the most proximal part of the stent structure, which no longer belongs to the effective length and in which the struts / wires run towards the insertion aid.
- a typical length of this proximal end is 8 to 10 mm, d. H. the total length of the stent structure is about this amount longer than the effective length of the stent structure.
- the struts or wires can here have a larger cross-section than in the middle section.
- the struts / wires are thus made more massive, whereby the basic tendency of a stent structure to exert higher radial forces in the middle section is compensated in whole or in part.
- the density of the struts or wires may be higher in the proximal section than in the middle section. Also by this measure, the drop in radial force to be observed in conventional stents is compensated for proximally or distally in whole or in part. It is also possible to provide the stent structure with a slot which extends helically over the lateral surface of the stent structure or longitudinally along the lateral surface of the stent structure. In this case, individual struts or wires can span the slot, so as to influence the radial force curve.
- the diameter of the stent structure in the expanded state is typically in the range of 2 to 8 mm, preferably in the range of 4 to 6 mm.
- the total length of the stent structure in the expanded state is usually 5 to 50 mm, preferably 10 to 45 mm, more preferably 20 to 40 mm.
- the length of the stent structure in the expanded state, which actually exerts radial forces on the vessel inner wall, is usually about 8 to 10 mm shorter.
- the radiopaque markers may, for. From platinum, palladium, platinum-iridium, tantalum, gold, tungsten or other radiopaque metals.
- radiopaque coils may be mounted at various points on the device. It is also possible to provide the stent structure, in particular the struts or wires of the stent structure with a coating of a radiopaque material, for example with a gold coating. This can, for. B. have a thickness of 1 to 6 ⁇ .
- the coating with a radiopaque material need not cover the entire stent structure; It is particularly important in the areas of the stent structure that touch the vessel inner wall, d. H. essentially in the cylindrical part of the Stenpatented. However, even when providing a radiopaque coating, it may be useful to additionally attach one or more radiopaque markers to the device, in particular at the distal end of the stent structure.
- the invention also relates to a method for vasospasm treatment, wherein a device of the type described above is used.
- the stent structure of the device is brought to the position of the vasospasm by means of the insertion aid and expanded there, which is usually done by retracting the microcatheter in which the device is housed in the proximal direction.
- the stent structure is left for a few minutes, preferably 1 to 10 minutes.
- the stent structure is removed from the blood vessel.
- the microcatheter can be advanced distally to refold the stent structure and accommodate it in the microcatheter.
- Microcatheter and device can then be withdrawn and removed from the blood vessel system. It makes sense to repeat the described treatment on several consecutive days in order to continue the vasospasm treatment.
- FIG. 1 a A device according to the invention in the
- FIG. 1 a in a developed view
- Figure 2 is an illustration of the radial force level along the stent structure
- FIG. 3 shows a measuring apparatus for determining the radial force exerted by the stent structure
- Figure 4 the determination of the effective length of the
- FIG. 1 a the device 1 according to the invention is shown in side view.
- the device has a stent structure 2 and an insertion aid 3 in FIG Shape of an insertion wire on.
- the stent structure 2 is laser-cut in this example and is composed of struts, which give a total of a continuous honeycomb structure.
- the insertion aid 3 is eccentric, ie connected in the edge region with the stent structure 2 at its proximal end.
- FIG. 1 b shows the device 1 from FIG. 1 a unwound, ie the hypothetical situation which would result if the essentially cylindrical stent structure 2 from FIG. 1 a were cut open along the longitudinal axis and spread out flat.
- the insertion aid 3 is shown here only shortened.
- FIG. 2 shows the course of the radial force (COF) along the stent structure 2 according to a preferred embodiment. Only at the proximal end does a lower radial force act on the surrounding vessel inner wall, moreover the radial force is constant over the entire stent structure 2. The decrease of the radial force at the proximal end is related to the fact that here the stent structure 2 converges to the insertion aid 3 in one point and the stent structure 2 therefore does not cover the entire circumference of the vessel inner wall.
- FIG. 3 shows a device for determining the radial force by means of a V-block test for the stent structure 2.
- the device for determining the radial force has 2 V blocks 4, which are each provided with a 90 ° V-groove. When placing the V-blocks 4 thus creates a cavity with square cross-section. While the lower V-block 4 is fixed, the upper V-block 4 has a force sensor to detect the radial force.
- the stent structure 2 to be tested is first inserted into the square cavity between the V-blocks 4 within a transport tube or microcatheter. Subsequently, the tube / microcatheter is withdrawn so that the self-expanding stent structure 2 can expand to the faces of the V-blocks 4.
- the forces exerted by the stent structure 2 are indicated by the dashed arrows and are transmitted via the V blocks 4 to the force sensor and evaluated.
- the relative radial force is used, ie absolute radial force with respect to the effective length 5 of the stent structure 2.
- the stent structure is pulled into a transparent tube 6 with a round cross section.
- the effective length 5 is the length in which the stent structure 2 covers at least 50% of the circumference.
- FIG. 5 shows a preferred embodiment of a stent structure 2 according to the invention in a side view, wherein the stent structure 2 is divided into a proximal section 7, a middle section 8 and a distal section 9.
- the presentation is limited to the effective length 5, d. H. neither the proximal end nor the insertion aid are shown.
- this is a stent structure 2 of individual wires forming a mesh structure.
- the density of the mesh structure is increased both in the proximal section 7 and in the distal section 9 in relation to the central section 8. The regularly observed decrease in the radial force to the proximal and distal with uniformly structured stent structures 2 is thus compensated by the higher density of wires.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Prostheses (AREA)
- Surgical Instruments (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102016110199.0A DE102016110199A1 (de) | 2016-06-02 | 2016-06-02 | Vasospasmusbehandlung |
PCT/EP2017/063302 WO2017207689A1 (de) | 2016-06-02 | 2017-06-01 | Vasospasmusbehandlung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3463206A1 true EP3463206A1 (de) | 2019-04-10 |
Family
ID=59253452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17733977.7A Pending EP3463206A1 (de) | 2016-06-02 | 2017-06-01 | Vasospasmusbehandlung |
Country Status (12)
Country | Link |
---|---|
US (1) | US11382778B2 (de) |
EP (1) | EP3463206A1 (de) |
JP (1) | JP7056935B2 (de) |
KR (1) | KR102460929B1 (de) |
CN (1) | CN109310506B (de) |
AR (1) | AR108655A1 (de) |
AU (1) | AU2017275732B2 (de) |
BR (1) | BR112018074618A2 (de) |
CA (1) | CA3025967A1 (de) |
DE (1) | DE102016110199A1 (de) |
SG (1) | SG11201810710WA (de) |
WO (1) | WO2017207689A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10888414B2 (en) | 2019-03-20 | 2021-01-12 | inQB8 Medical Technologies, LLC | Aortic dissection implant |
CN116033883A (zh) * | 2020-09-11 | 2023-04-28 | Jmr株式会社 | 支架以及支架的制造方法 |
DE102021102458A1 (de) | 2021-01-26 | 2022-07-28 | Phenox Gmbh | Beschichtete medizinische Vorrichtungen |
WO2022161813A1 (de) | 2021-01-26 | 2022-08-04 | Phenox Gmbh | Beschichtete medizinische vorrichtungen |
DE102022113422A1 (de) | 2022-05-27 | 2023-11-30 | Acandis Gmbh | Stent und Behandlungssystem mit einem solchen Stent |
DE102022114767A1 (de) | 2022-06-13 | 2023-12-14 | Phenox Gmbh | Endovaskuläre Vorrichtung mit Führungsdraht |
WO2024018367A1 (en) | 2022-07-22 | 2024-01-25 | Phenox Gmbh | Apparatus and method for treating vasospasm |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE850C (de) * | 1877-09-11 | A. KOCH & F. SCHAACK in Köln | Elektromagnetische Normaluhr | |
US5449372A (en) * | 1990-10-09 | 1995-09-12 | Scimed Lifesystems, Inc. | Temporary stent and methods for use and manufacture |
US6258032B1 (en) * | 1997-01-29 | 2001-07-10 | William M. Hammesfahr | Method of diagnosis and treatment and related compositions and apparatus |
JPH105343A (ja) * | 1996-06-21 | 1998-01-13 | Piolax Inc | 管状器官の治療具 |
DE10233085B4 (de) | 2002-07-19 | 2014-02-20 | Dendron Gmbh | Stent mit Führungsdraht |
DE10301850B4 (de) * | 2003-01-16 | 2017-05-04 | Dendron Gmbh | Stent |
JP4566988B2 (ja) | 2003-04-02 | 2010-10-20 | ボストン サイエンティフィック リミテッド | 分離及び回収可能なステントアセンブリ |
US8623067B2 (en) | 2004-05-25 | 2014-01-07 | Covidien Lp | Methods and apparatus for luminal stenting |
EP1604697A1 (de) * | 2004-06-09 | 2005-12-14 | J.A.C.C. GmbH | Implantierbare Vorrichtung |
DE102007012964A1 (de) | 2007-03-06 | 2008-09-11 | Phenox Gmbh | Implantat zur Beeinflussung des Blutflusses |
US8066757B2 (en) | 2007-10-17 | 2011-11-29 | Mindframe, Inc. | Blood flow restoration and thrombus management methods |
US20110009941A1 (en) | 2009-07-08 | 2011-01-13 | Concentric Medical, Inc. | Vascular and bodily duct treatment devices and methods |
US8529596B2 (en) * | 2009-07-08 | 2013-09-10 | Concentric Medical, Inc. | Vascular and bodily duct treatment devices and methods |
US9039749B2 (en) | 2010-10-01 | 2015-05-26 | Covidien Lp | Methods and apparatuses for flow restoration and implanting members in the human body |
AU2013207123B2 (en) * | 2012-01-04 | 2018-03-01 | Rapid Medical Ltd. | Braided devices for assisting medical treatments |
US20160081825A1 (en) * | 2012-01-04 | 2016-03-24 | Rapid Medical Ltd. | Heat-treated braided intravascular devices and methods |
JP6463132B2 (ja) * | 2012-01-17 | 2019-01-30 | パーフロー メディカル リミテッド | 閉塞物を除去する装置 |
KR101871144B1 (ko) | 2012-03-16 | 2018-06-27 | 마이크로벤션, 인코포레이티드 | 스텐트 및 스텐트 전달 장치 |
US20180271683A1 (en) * | 2015-09-30 | 2018-09-27 | Neurvana Medical, Llc | Treatment Systems Processes and Devices Addressing Cerebral Vasospasm/Vasoconstriction |
-
2016
- 2016-06-02 DE DE102016110199.0A patent/DE102016110199A1/de active Pending
-
2017
- 2017-06-01 JP JP2018562307A patent/JP7056935B2/ja active Active
- 2017-06-01 SG SG11201810710WA patent/SG11201810710WA/en unknown
- 2017-06-01 WO PCT/EP2017/063302 patent/WO2017207689A1/de unknown
- 2017-06-01 AR ARP170101496A patent/AR108655A1/es active IP Right Grant
- 2017-06-01 BR BR112018074618-5A patent/BR112018074618A2/pt not_active Application Discontinuation
- 2017-06-01 CN CN201780034478.8A patent/CN109310506B/zh active Active
- 2017-06-01 KR KR1020187035574A patent/KR102460929B1/ko active IP Right Grant
- 2017-06-01 US US16/306,500 patent/US11382778B2/en active Active
- 2017-06-01 AU AU2017275732A patent/AU2017275732B2/en active Active
- 2017-06-01 CA CA3025967A patent/CA3025967A1/en active Pending
- 2017-06-01 EP EP17733977.7A patent/EP3463206A1/de active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3025967A1 (en) | 2017-12-07 |
AU2017275732A1 (en) | 2019-01-24 |
JP7056935B2 (ja) | 2022-04-19 |
KR102460929B1 (ko) | 2022-10-31 |
KR20190014513A (ko) | 2019-02-12 |
US20190110912A1 (en) | 2019-04-18 |
CN109310506B (zh) | 2022-02-08 |
US11382778B2 (en) | 2022-07-12 |
JP2019517300A (ja) | 2019-06-24 |
WO2017207689A1 (de) | 2017-12-07 |
AR108655A1 (es) | 2018-09-12 |
CN109310506A (zh) | 2019-02-05 |
AU2017275732B2 (en) | 2022-06-30 |
DE102016110199A1 (de) | 2017-12-07 |
BR112018074618A2 (pt) | 2019-03-06 |
SG11201810710WA (en) | 2019-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017207689A1 (de) | Vasospasmusbehandlung | |
EP2613743B1 (de) | Implantat zur beeinflussung des blutflusses bei arteriovenösen fehlbildungen | |
DE602004012037T2 (de) | Abdeckvorrichtung für einen Aneurysemhals | |
EP1542617A1 (de) | Medizinisches implantat | |
EP3041439B9 (de) | Einführ- und ablösesystem für implantate | |
WO2016139357A1 (de) | Implantateinführsystem | |
WO2017114879A1 (de) | SELBSTEXPANDIERENDE GEFÄßPROTHESE | |
WO2021028161A1 (de) | Medizinisches set zur behandlung von aneurysmen, herstellungsverfahren sowie medizinisches system zur behandlung von aneurysmen | |
EP1903952A1 (de) | Endovaskulares implantat für den verschluss eines blutgefässes | |
WO2017089451A1 (de) | Bandförmiges okklusionsmittel | |
DE102018133345B4 (de) | Stent | |
EP3764928A1 (de) | Thrombektomievorrichtung | |
EP4027910A1 (de) | Implantat zur behandlung von aneurysmen | |
WO2019174991A1 (de) | Temporärer verschluss von aneurysmenhälsen | |
WO2021250281A1 (de) | Implantat zur behandlung von aneurysmen | |
DE10301600A1 (de) | Kombination von Stents | |
EP3781088B1 (de) | Vorrichtung zur einbringung von implantaten | |
WO2023104590A1 (de) | Implantat zur behandlung von aneurysmen im bereich von bifurkationen | |
EP2982392A1 (de) | Medizinische vorrichtung zur behandlung von neurovaskulären erkrankungen sowie system und set mit einer derartigen vorrichtung | |
DE102015121531B4 (de) | Medizinisches System zur Behandlung von Aneurysmen | |
DE102020115600A1 (de) | Implantat zur Behandlung von Aneurysmen | |
WO2023242086A1 (de) | Endovaskuläre vorrichtung mit führungsdraht | |
EP3549518A1 (de) | Haltestruktur für ein implantat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190102 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FEMTOS GMBH Owner name: CHARITE - UNIVERSITAETSMEDIZIN BERLIN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230630 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240603 |